IDH status is also useful in predicting the OS of patients diagnosed with GBM, and in the selection of appropriate therapeutic strategies [40,41], however, the majority of grade II and III gliomas have a mutant-type of IDH (Figure 2), while survival times vary between these patients (Figure 4C). Here, IDH1 is linked to central nervous system cancer.